Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

2024-9-17

Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis

2024-9-17

Cancer in multi-lineage mosaic RASopathies due to pathogenic variants in HRAS or KRAS: a systematic review and meta-analysis

2024-9-17

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer

2024-9-17

Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group

2024-9-13

Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer.

2024-9-13

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer

2024-9-13

MEK inhibitors lead to PDGFR pathway upregulation and sensitize tumors to RAF dimer inhibitors in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)

2024-9-13

TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma

2024-9-12

The Epstein-Barr virus nuclear antigen 1 variant associated with nasopharyngeal carcinoma defines the sequence criteria for serologic risk prediction

2024-9-12

Hepatocellular Carcinoma Immune Microenvironment Analysis: A Comprehensive Assessment with Computational and Classical Pathology

2024-9-12

Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders

2024-9-12

A first-in-human phase 1 study of BXQ-350, a first-in-class sphingolipid metabolism regulator, in patients with advanced/recurrent solid tumors or high-grade gliomas

2024-9-12

Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma

2024-9-11

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients

2024-9-11

The intrauterine device: how to deploy this strategy in the molecular world?

2024-9-10

ctDNA dynamics and mechanisms of acquired resistance in patients treated with osimertinib with or without bevacizumab from the randomised phase II ETOP-BOOSTER trial

2024-9-9

FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma

2024-9-9

Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival

2024-9-9

A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies

2024-9-5

FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

2024-9-4

Genomic profiling and immune phenotyping of neuroendocrine bladder cancer

2024-9-3

Understanding and Overcoming Resistance to Selective FGFR inhibitors Across <i>FGFR2</i>-Driven Malignancies

2024-9-3

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

2024-9-3

A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer

2024-9-3

Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2024-9-3

Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF

2024-8-30

Exploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma

2024-8-29

A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy

2024-8-28

Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia

2024-8-28

Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathies

2024-8-28

Pediatric cancer screening in hereditary gastrointestinal cancer risk syndromes: An update from the AACR Childhood Cancer Predisposition Working Group

2024-8-27

Translational Imaging in Cerebral Tumors

2024-8-23

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer

2024-8-23

Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns

2024-8-23

Genetic Screen in a Pre-Clinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities

2024-8-23

Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis

2024-8-21

A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES

2024-8-21

KIR2DL2/DL3+NKs and Helios+Tregs in peripheral blood predict nivolumab response in patients with metastatic renal cell cancer

2024-8-21

The infiltrative margins in glioblastoma: important is what has been left behind

2024-8-20

Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer

2024-8-20

Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy

2024-8-20

Novel <i>ERBB2</i> Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in <i>ERBB2</i>-Amplified Metastatic Colorectal Cancer

2024-8-20

Dendritic Cell Plasticity, Radiation, and Newton's Third Law

2024-8-19

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

2024-8-16

Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs

2024-8-16

Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome

2024-8-16

Transcriptomic heterogeneity of <i>EGFR</i>-mutant non-small cell lung cancer evolution towards small cell lung cancer

2024-8-16

The Impact of Li Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes and Genetic Testing Recommendations

2024-8-16

Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for immune checkpoint inhibitors in biliary tract cancer

2024-8-16